Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Arix Bioscience plc
  6. News
  7. Summary
    ARIX   GB00BD045071

ARIX BIOSCIENCE PLC

(ARIX)
  Report
Delayed Quote. Delayed London Stock Exchange - 10/26 11:35:28 am
138 GBX   -2.13%
10/18LogicBio Therapeutics Announces Early Clinical -2-
DJ
10/18ARIX BIOSCIENCE : Cancels Share Repurchase Program to Focus on Investments
MT
10/18Business Update and Cancellation of Share Buyback
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Transaction in own shares

08/31/2021 | 12:31pm EDT

Arix Bioscience PLC (ARIX) Transaction in own shares 31-Aug-2021 / 17:30 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

Arix Bioscience plc

Transaction in own shares

LONDON, 31 August 2021: Arix Bioscience plc ("Arix" or "the Company") (LSE:ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that it purchased the following number of its ordinary shares of 0.001 pence each on the London Stock Exchange from Jefferies International Limited as part of a buyback programme announced on 22 March 2021.

Date of purchase                      31 August 2021 
Aggregate number of shares purchased  30,000 
Highest price paid per share          173.00p 
Lowest price paid per share           172.00p 
Average price paid per share          172.33p 

Arix intends to retain the purchased shares in treasury.

Following settlement of the above purchase, Arix will have 130,455,800 ordinary shares of 0.001 pence each in issue (excluding 5,153,853 ordinary shares of 0.001p each held in treasury). This number represents the total voting rights in Arix and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), the schedule below contains detailed information of the individual trades made by Jefferies International Limited as part of the buyback programme.

[ENDS]

For more information on Arix, please contact:

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

Optimum Strategic Communications

Mary Clark, Manel Mateus

+44 (0)20 8078 4357

optimum.arix@optimumcomms.com

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

Transaction Date Transaction Time Volume Price (GBp) Platform              Transaction Reference Number 
31/08/2021       08:07:01         10,000 173.00      London Stock Exchange 00259203329TRLO1 
31/08/2021       10:14:54         20,000 172.00      London Stock Exchange 00259293175TRLO1 

-----------------------------------------------------------------------------------------------------------------------

ISIN:           GB00BD045071 
Category Code:  POS 
TIDM:           ARIX 
LEI Code:       213800OVT3AHQCXNIX43 
OAM Categories: 2.4. Acquisition or disposal of the issuer's own shares 
Sequence No.:   121166 
EQS News ID:    1230242 
 
End of Announcement  EQS News Service 
=------------------------------------------------------------------------------------
 

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1230242&application_name=news

(END) Dow Jones Newswires

August 31, 2021 12:30 ET (16:30 GMT)

All news about ARIX BIOSCIENCE PLC
10/18LogicBio Therapeutics Announces Early Clinical -2-
DJ
10/18ARIX BIOSCIENCE : Cancels Share Repurchase Program to Focus on Investments
MT
10/18Business Update and Cancellation of Share Buyback
DJ
10/18Tranche Update on Arix Bioscience plc's Equity Buyback Plan announced on March 15, 2021..
CI
10/18Arix Bioscience plc's Equity Buyback announced on March 15, 2021, has expired with 6,42..
CI
10/15Transaction in own shares
DJ
10/13Transaction in own shares
DJ
10/13TR1 : Notification of Major Shareholding -2-
DJ
10/13TR1 : Notification of Major Shareholding
DJ
10/12ARIX BIOSCIENCE : Investee Aura Biosciences Posts Interim Data from Choroidal Melanoma Dru..
MT
More news
Financials
Sales 2021 - - -
Net income 2021 - - -
Net cash 2021 133 M 183 M 183 M
P/E ratio 2021 -
Yield 2021 -
Capitalization 171 M 236 M 236 M
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 12
Free-Float 72,1%
Chart ARIX BIOSCIENCE PLC
Duration : Period :
Arix Bioscience plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARIX BIOSCIENCE PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 138,00 GBX
Average target price 256,00 GBX
Spread / Average Target 85,5%
EPS Revisions
Managers and Directors
Robert William Henry Lyne CEO, COO, Secretary, Director & General Counsel
Marcus Karia Group Finance Director
Peregrine D. E. M. Moncreiffe Non-Executive Chairman
Graeme Smith Chief Technology Officer
Michael William Bunbury Senior Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ARIX BIOSCIENCE PLC-36.99%241
INVESTOR AB (PUBL)33.69%71 019
CK HUTCHISON HOLDINGS LIMITED-2.40%26 106
GROUPE BRUXELLES LAMBERT SA20.72%17 481
HAL TRUST30.05%14 939
AB INDUSTRIVÄRDEN (PUBL)2.92%14 176